Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation.

Lu C, Waugh A, Bailey RJ, Cherry R, Dieleman LA, Gramlich L, Matic K, Millan M, Kroeker KI, Sadowski D, Teshima CW, Todoruk D, Wong C, Wong K, Fedorak RN.

World J Gastroenterol. 2012 Sep 28;18(36):5058-64. doi: 10.3748/wjg.v18.i36.5058.

2.

NOD2/CARD15 does not influence response to infliximab in Crohn's disease.

Vermeire S, Louis E, Rutgeerts P, De Vos M, Van Gossum A, Belaiche J, Pescatore P, Fiasse R, Pelckmans P, Vlietinck R, Merlin F, Zouali H, Thomas G, Colombel JF, Hugot JP; Belgian Group of Infliximab Expanded Access Program and Fondation Jean Dausset CEPH, Paris, France.

Gastroenterology. 2002 Jul;123(1):106-11.

3.

IBD5 polymorphisms in inflammatory bowel disease: association with response to infliximab.

Urcelay E, Mendoza JL, Martinez A, Fernandez L, Taxonera C, Diaz-Rubio M, de la Concha EG.

World J Gastroenterol. 2005 Feb 28;11(8):1187-92.

4.

CARD15 mutations in Dutch familial and sporadic inflammatory bowel disease and an overview of European studies.

van der Linde K, Boor PP, Houwing-Duistermaat JJ, Crusius BJ, Wilson PJ, Kuipers EJ, de Rooij FW.

Eur J Gastroenterol Hepatol. 2007 Jun;19(6):449-59. Review.

PMID:
17489054
5.

Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials.

Mascheretti S, Hampe J, Croucher PJ, Nikolaus S, Andus T, Schubert S, Olson A, Bao W, Fölsch UR, Schreiber S.

Pharmacogenetics. 2002 Oct;12(7):509-15.

PMID:
12360101
7.

Clinical significance of NOD2/CARD15 and Toll-like receptor 4 gene single nucleotide polymorphisms in inflammatory bowel disease.

Rigoli L, Romano C, Caruso RA, Lo Presti MA, Di Bella C, Procopio V, Lo Giudice G, Amorini M, Costantino G, Sergi MD, Cuppari C, Calabro GE, Gallizzi R, Salpietro CD, Fries W.

World J Gastroenterol. 2008 Jul 28;14(28):4454-61.

8.

Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease.

Gutiérrez A, Scharl M, Sempere L, Holler E, Zapater P, Almenta I, González-Navajas JM, Such J, Wiest R, Rogler G, Francés R.

Gut. 2014 Feb;63(2):272-80. doi: 10.1136/gutjnl-2012-303557. Epub 2013 Feb 1.

PMID:
23376290
9.

Interaction of the major inflammatory bowel disease susceptibility alleles in Crohn's disease patients.

Csöngei V, Járomi L, Sáfrány E, Sipeky C, Magyari L, Faragó B, Bene J, Polgár N, Lakner L, Sarlós P, Varga M, Melegh B.

World J Gastroenterol. 2010 Jan 14;16(2):176-83.

10.

Perianal Crohn's disease: predictive factors and genotype-phenotype correlations.

Kanaan Z, Ahmad S, Bilchuk N, Vahrenhold C, Pan J, Galandiuk S.

Dig Surg. 2012;29(2):107-14. doi: 10.1159/000335745. Epub 2012 Mar 22.

11.

Prediction of Crohn's disease aggression through NOD2/CARD15 gene sequencing in an Australian cohort.

Bhullar M, Macrae F, Brown G, Smith M, Sharpe K.

World J Gastroenterol. 2014 May 7;20(17):5008-16. doi: 10.3748/wjg.v20.i17.5008.

12.

Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remission.

Papamichael K, Vande Casteele N, Gils A, Tops S, Hauenstein S, Singh S, Princen F, Van Assche G, Rutgeerts P, Vermeire S, Ferrante M.

Clin Gastroenterol Hepatol. 2015 Jun;13(6):1103-10. doi: 10.1016/j.cgh.2014.11.026. Epub 2014 Dec 3.

PMID:
25478919
13.

NOD2/CARD15 gene polymorphisms in Crohn's disease: a genotype- phenotype analysis.

Heresbach D, Gicquel-Douabin V, Birebent B, D'halluin PN, Heresbach-Le Berre N, Dreano S, Siproudhis L, Dabadie A, Gosselin M, Mosser J, Semana G, Bretagne JF, Yaouanq J.

Eur J Gastroenterol Hepatol. 2004 Jan;16(1):55-62.

PMID:
15095853
14.

CARD15/NOD2, CD14 and toll-like 4 receptor gene polymorphisms in Saudi patients with Crohn's Disease.

Azzam N, Nounou H, Alharbi O, Aljebreen A, Shalaby M.

Int J Mol Sci. 2012;13(4):4268-80. doi: 10.3390/ijms13044268. Epub 2012 Apr 2.

15.

NOD2/CARD15, ATG16L1 and IL23R gene polymorphisms and childhood-onset of Crohn's disease.

Gazouli M, Pachoula I, Panayotou I, Mantzaris G, Chrousos G, Anagnou NP, Roma-Giannikou E.

World J Gastroenterol. 2010 Apr 14;16(14):1753-8.

16.

Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial.

Buhl SS, Steenholdt C, Brynskov J, Thomsen OØ, Bendtzen K, Ainsworth MA.

BMJ Open. 2014 Dec 18;4(12):e005887. doi: 10.1136/bmjopen-2014-005887.

17.

CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn's disease.

Heliö T, Halme L, Lappalainen M, Fodstad H, Paavola-Sakki P, Turunen U, Färkkilä M, Krusius T, Kontula K.

Gut. 2003 Apr;52(4):558-62.

18.

Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up.

Caviglia R, Ribolsi M, Rizzi M, Emerenziani S, Annunziata M, Cicala M.

World J Gastroenterol. 2007 Oct 21;13(39):5238-44.

19.

Repeated exclusive enteral nutrition in the treatment of paediatric Crohn's disease: predictors of efficacy and outcome.

Frivolt K, Schwerd T, Werkstetter KJ, Schwarzer A, Schatz SB, Bufler P, Koletzko S.

Aliment Pharmacol Ther. 2014 Jun;39(12):1398-407. doi: 10.1111/apt.12770. Epub 2014 Apr 30.

20.

Supplemental Content

Support Center